We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+27.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.71B
AUM Growth
+$107M
Cap. Flow
-$182M
Cap. Flow %
-10.62%
Top 10 Hldgs %
37.71%
Holding
102
New
9
Increased
24
Reduced
36
Closed
9

Top Buys

Rank Stock Value
1
HTFL
Heartflow Inc
HTFL
+$8.04M
2
CDTX
Cidara Therapeutics
CDTX
+$7.36M
3
LENZ
LENZ Therapeutics
LENZ
+$5.6M
4
TVTX icon
Travere Therapeutics
TVTX
+$4.82M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.15M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$30.4M
2
BPMC
Blueprint Medicines
BPMC
+$23.8M
3
ARGX icon
argenx
ARGX
+$21.8M
4
INSM icon
Insmed
INSM
+$17.2M
5
UNH icon
UnitedHealth
UNH
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVH icon
26
Evolent Health
EVH
$444M
$25M 1.46%
2,950,000
+129,300
+5% +$1.25M
CAI
27
Caris Life Sciences
CAI
$6.61B
$24M 1.4%
793,651
– –
CDTX
28
DELISTED
Cidara Therapeutics
CDTX
$23.9M 1.4%
249,402
+115,269
+86% +$7.36M
DXCM icon
29
DexCom
DXCM
$33.1B
$21.3M 1.25%
316,900
+30,150
+11% +$2.39M
OMDA
30
Omada Health Inc
OMDA
$1.49B
$20.3M 1.19%
919,950
-1
-0% -$20
CLDX icon
31
Celldex Therapeutics
CLDX
$3.37B
$18.7M 1.09%
721,538
-91,115
-11% -$2.11M
VERA icon
32
Vera Therapeutics
VERA
$2.27B
$17.9M 1.05%
617,396
– –
PHR icon
33
Phreesia
PHR
$769M
$17.6M 1.03%
749,116
-88,184
-11% -$2.4M
TARS icon
34
Tarsus Pharmaceuticals
TARS
$2.97B
$17.1M 1%
288,344
-85,406
-23% -$4.2M
NAMS icon
35
NewAmsterdam Pharma
NAMS
$3.34B
$16.9M 0.99%
595,929
+59,818
+11% +$1.43M
CMPX icon
36
Compass Therapeutics
CMPX
$400M
$15.7M 0.92%
4,474,702
-488,253
-10% -$1.54M
PHVS icon
37
Pharvaris
PHVS
$2.43B
$15.6M 0.91%
623,402
– –
AZTA icon
38
Azenta
AZTA
$1.54B
$15.5M 0.91%
540,400
+10,000
+2% +$310K
MLYS icon
39
Mineralys Therapeutics
MLYS
$2.41B
$15.5M 0.9%
408,313
+83,800
+26% +$1.81M
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$15.3M 0.9%
1,947,374
-12,960
-0.7% -$92.2K
XBI icon
41
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$15.2M 0.89%
151,750
– –
ACLX
42
DELISTED
Arcellx
ACLX
$14.7M 0.86%
178,982
-7,332
-4% -$528K
SMMT icon
43
Summit Therapeutics
SMMT
$11.9B
$14.7M 0.86%
710,000
– –
COGT icon
44
Cogent Biosciences
COGT
$7.1B
$14.5M 0.85%
1,008,308
+208,109
+26% +$2.47M
ELVN icon
45
Enliven Therapeutics
ELVN
$4.35B
$14M 0.82%
686,107
-15,301
-2% -$308K
ZBIO
46
Zenas BioPharma
ZBIO
$2.02B
$12.9M 0.75%
580,677
-59,790
-9% -$973K
NBIX icon
47
Neurocrine Biosciences
NBIX
$16.8B
$12.6M 0.74%
89,750
+950
+1% +$129K
ARDX icon
48
Ardelyx
ARDX
$997M
$12.6M 0.74%
2,286,273
– –
DHR icon
49
Danaher
DHR
$147B
$12.2M 0.71%
61,500
+2,500
+4% +$497K
LENZ
50
LENZ Therapeutics
LENZ
$168M
$11M 0.64%
236,227
+152,245
+181% +$5.6M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Rock Springs Capital Management held 102 positions worth $1.71B, up 6.7% from $1.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Rock Springs Capital Management withdrew a net $182M in Q3 2025, closing 9 positions and reducing 36 holdings. Its most notable exit was Blueprint Medicines, an estimated $23.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, Rock Springs Capital Management opened a new position in Heartflow Inc worth $8.41M.

  • Rock Springs Capital Management's largest Q3 2025 buy was Heartflow Inc: 250,000 shares worth $8.41M.
  • Rock Springs Capital Management added most to Cidara Therapeutics in Q3 2025, an estimated $7.36M increase.
  • Rock Springs Capital Management's biggest Q3 2025 reduction was Merus, cutting an estimated $30.4M.
  • Rock Springs Capital Management fully exited Blueprint Medicines in Q3 2025, selling an estimated $23.8M.
  • Rock Springs Capital Management's ten largest holdings make up 38% of its $1.71B portfolio in Q3 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 9 in Q3 2025.
  • Rock Springs Capital Management's portfolio value rose 6.7% quarter-over-quarter to $1.71B.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.